Desoize B, Bouche O, Berthiot G, Coninx P
IFR53-EA2063, Laboratoire de Biochimie, Reims, France.
Anticancer Res. 1998 Nov-Dec;18(6B):4607-10.
The pharmacokinetics of fluorouracil (5FU) were studied in two groups of patients, the administration of 105 i.v. as daily bolus (x5) or 5-day continuous infusions. The 5FU pharmacokinetics were extremely variable from day to day, i.e. from one bolus to the next or during the continuous infusion, especially in some patients. The variations were lower for the daily bolus, but still remained high. The pharmacokinetics of cisplatin, given simultaneously during continuous infusions did not show the same variability; therefore the variability could be specific for 5FU. The role of implantable subcutaneous ports as the most probable source of this extraordinary variability is discussed. We hypothesise that in some patients the implantable subcutaneous ports used for 5FU infusion, could cause transient and extremely high plasma concentrations, exacerbated by the very short half life of the drug and by saturation of its catabolism.
在两组患者中研究了氟尿嘧啶(5-氟尿嘧啶,5FU)的药代动力学,一组患者接受105mg静脉推注(每日一次,共5次),另一组患者接受为期5天的持续静脉输注。5FU的药代动力学在不同日期变化极大,即在一次推注与下一次推注之间或在持续输注期间,尤其是在部分患者中。每日推注时的变化较小,但仍处于较高水平。在持续输注期间同时给予的顺铂药代动力学未表现出相同的变异性;因此,这种变异性可能是5FU所特有的。文中讨论了可植入皮下端口作为这种异常变异性最可能来源的作用。我们推测,在部分患者中,用于输注5FU的可植入皮下端口可能会导致短暂且极高的血浆浓度,药物极短的半衰期及其分解代谢的饱和会加剧这种情况。